Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab

Randomized controlled clinical trials and real-life observations indicate that less than 50% of patients with Crohn’s disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a humanized monoclonal antibody that blocks the α4β7 integrin. Since α4β7-expressing lymphocytes mainly infiltrate the...

Full description

Bibliographic Details
Main Authors: Patrizio Scarozza, Irene Marafini, Federica Laudisi, Edoardo Troncone, Heike Schmitt, Marco Vincenzo Lenti, Stefania Costa, Irene Rocchetti, Elena De Cristofaro, Silvia Salvatori, Ludovica Frezzati, Antonio Di Sabatino, Raja Atreya, Markus F. Neurath, Emma Calabrese, Giovanni Monteleone
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Journal of Clinical Medicine
Subjects:
inflammatory bowel disease
crohn’s disease
alpha4beta7 integrin
biologics
Online Access:https://www.mdpi.com/2077-0383/9/2/385

Internet

https://www.mdpi.com/2077-0383/9/2/385

Similar Items